SI Materials and Methods
Molecular dynamics simulations Unbiased all-atom molecular dynamics (MD) simulations of the x-ray crystal structure of FFAR1 in presence and absence of TAK-875 were performed using GROMACS 4.6.5(1) , the CHARMM36 forcefield (2) and the TIP3P water model. For the computation of electrostatic interactions, the particle-mesh Ewald method was applied (3) . We generated a full-length model of hFFAR1 based on the x-ray crystal structure of FFAR1 (PDB 4PHU) using ICM(4) (Molsoft L.L.C.), which was consequently embedded into a 50 ns preequilibrated palmitoyl-2-oleoylsn-glycero-3-phosphatidylcholine (POPE) membrane using g_membed (5) . After solvation in a cuboid box, Na + and Clions were added to neutralize the overall electric charge and to model an ion concentration of 0.15 M. A steepestdescent energy minimization was conducted and the system containing TAK-875, including the system in which TAK-875 was added after 600 ns, was equilibrated in the NPT ensemble for 40 ns, controlled by a Parrinello-Rahman barostat and V-rescale thermostat (6) , using decreasing position restraints as follows: 10 ns with 100.000 kJ/mol Å 2 position restraints on the protein, ligand, water and ions followed by 30 ns with gradually decreasing position restraints on the protein backbone and ligand (10 ns for each 100.000, 10.000 and 2000 kJ/mol Å 2 ). TAK-875 was added after 600 ns by superimposing the representative cluster #1 center structures, extracted from the simulation in presence and absence of TAK-875. The rotameric state of F142 was manually altered to avoid clashes with TAK-875. Electrostatic partial charges for TAK-875 were obtained by electrostatic fitting using Gaussian 09 revision D.01 (7) at the RHF/6-31G* level of theory. The force field toolkit of VMD (8) was used for the setup of TAK-875. 600 ns of MD production run were carried out for each system. Representative structures for the extracellular and inter-helical sites were selected by performing a geometric clustering based on the 48 residues that form the extracellular site and the inter-helical binding site for TAK-875 and MK-8666, using a Cα-RMSD cutoff value of 1 Å to determine cluster-membership (SI Appendix, Fig. S3 ). The same procedure was applied for all Cα-atoms to select a representative overall receptor conformation (SI Appendix, Fig. S2A ) and with the Cα atoms of the eight residues of ICL2 (SI Appendix, Fig. S1B ) to identify a representative ICL2 conformation. Pocket volumes were calculated every 0.2 ns with the POVME algorithm (9) by aligning all conformations of the MD trajectory. To enhance the sampling on residues involved in the changes observed in the binding site upon removal of TAK-875 ( Fig. 1F) , we applied well-tempered metadynamics, using GROMACS 5.1.2/PLUMED 2.2.1(10) and the MD setup described above. We obtained free-energy profiles of selected atomic distances by carrying out 600 ns of metadynamics simulations of the apo-state receptor. We chose the atomic distances CV1=E65(Cδ)-R258(Cζ), CV2=Y240(OH)-K62(Nζ) and CV3=E65(Cδ)-R258(Cζ) (atom naming according to PDB standard) as collective variables to enhance the sampling of the conformational changes within the binding pocket, as observed in the unbiased MD simulation. For all CVs, the deposition rate of the Gaussian bias terms was set to 1 ps, and their initial height to 0.5 kJ/mol, their width to 3.5 Å, with a bias factor of 4.
Molecular docking and virtual ligand screening
We docked the In Stock subset of the ZINC database(11) containing 12,782,590 screening molecules that are pre-screened for 480 PAINS patterns, stripped for counterions and assigned tautomers, protonation states and charges, using SurflexDock (version 2.5)(12) with the options +premin, +remin into FFAR1's extracellular site, as defined by residues 2, 8, 12, 62, 65, 66, 82, 86, 87, 90, 172, 240, 258, 258, 263 . SurflexDock is based on a modified Hammerhead fragmentation/reconstruction algorithm to dock compounds flexibly into the binding site. Every ligand was decomposed into rigid fragments that are superimposed to a protomol, i.e. molecular fragments covering the binding site. Docking poses were ranked by an empirical scoring function. The 100,000 bestscored compounds (pre-filtered for crash score > -2, polar score > 2) were selected for a second docking protocol using ICM 4D docking (version 3.8-4a, Molsoft L.L.C.). The set of compounds was docked into an ensemble of four receptor structures, consisting of the cluster centers of the 4 largest clusters from the MD trajectory of FFAR1 in presence of TAK-875, representing 95.4 % of all trajectory frames. A set of chemical filtering criteria was applied (MW ≤ 500, logP ≤ 5, nrotb ≤ 12, VLS score ≤ -25, drug likeness score ≥ 0.2, internal ligand conformation energy ≤ 10) to yield 315 compounds from which a small library of 99 compounds was cherry-picked. 20-HETE was docked into the x-ray crystal structures of FFAR1 in complex with TAK-875 (PDB 4PHU) and MK-8666 & AP8 (PDB 5TZY) using ICM (version 3.8-4a, Molsoft L.L.C.). The receptor structure was converted into an ICM object, thereby assigning protein atom types optimizing hydrogens and His, Pro, Asn, Gly and Cys side chain conformations as well as removing crystallization water and co-crystal molecules. The extrahelical and inter-helical binding sites were identified using icmPocketFinder method(13) (default threshold 4.6). The docking procedure included: (i) Setup receptor; for each pocket the grid box was adjusted to cover all atoms within 15 Å from the center of the identified pockets. (ii) Setup batch ligand; (iii) run docking batch; thoroughness 10.0, assigning 3D ligand conformations, MMFF atom types and formal charges to ionizable groups. The ligand docking poses predicted for the three different pockets were ranked based on ICMs empirical scoring function, weighted according to the following parameters: (i) internal energy of the ligand, (ii) entropy loss of the ligand between bound and unbound states, (iii) ligand-receptor hydrogen bond interactions, (iv) polar and non-polar solvation energy differences between bound and unbound states, (v) electrostatic energy, (vi) hydrophobic energy, and (vii) hydrogen bond donor or acceptor desolvation -and therefore unitless. Generally a score below -32 is regarded as a good docking score based on assessments of ligand redocking scores of high-resolution protein-ligand complexes. Furthermore, the ligand conformational strain of all the best-scored docking poses was computed to confirm that the conformations of the bound ligands were accepted in low energy minimums. The final docking poses were not refined further e.g. by including side chain flexibility to certain side chains. Analogues of compound 1 were identified in a substructure search of chemical vendor catalogues using OpenBabel (14) and the smarts string "c:1(:n:c(:n:c(:n:1)[NH1]*)[NH2])***" as a search query. A total of 96 compounds was subsequently acquired from Enamine Ltd. based on manual inspection of the resulting hit list.
Compound preparation
The ligands TAK-875 and AM-5262 were synthesized as published (15, 16) and the modulator library was purchased (Enamine Ltd.). Stock solutions (1 mM) were prepared in 100 % DMSO and subsequently 10-fold serial diluted. TAK-875 and AM-5262 were further prepared at a concentration of 20 % DMSO. DMSO concentration in wells with cells did not exceed 2 %.
Molecular biology FFAR1 was cloned into the expression vector pCMV-Tag (2B) encoding a N-terminal FLAG tag epitope (Stratagene). The mutations were constructed by PCR using the QuickChange method with Pfu polymerase (Stratagene) according to manufacturer's instructions. Mutagenesis was verified by DNA sequence analysis by GATC Biotech (Constance, Germany).
Transfections and tissue culture COS7 cells were grown in Dulbecco's modified Eagle's medium 21885 (DMEM) supplemented with 10 % fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. For IP and cAMP accumulation assays, 20,000 cells/well were cultured overnight in 96-well plates and subsequently transiently transfected (400 ng DNA/well) using calcium phosphate precipitation method with chloroquine addition. The medium was changed after 5 h and cells were incubated overnight in 100 μl growth medium with 0.5 μCi/ml myo[ 3 H]inositol (IP accumulation) or without (cAMP). For binding experiments, 6 million COS7 cells cultured overnight in T175 flasks and subsequently transiently transfected (40 μg DNA/flask) using calcium phosphate precipitation method with chloroquine addition. After five hours the media was changed to growth media. The following day, 40,000 cells/well were seeded in 96-well plates and incubated overnight in 100 μl growth media.
IP accumulation assay
The day after transfection, cells were washed once with HBSS (Gibco, Life Technologies) and 100 µl HBSS supplemented with 10 mM LiCl were added prior to ligand addition. Ligands were added as dose-response curves (TAK-875, AM-5262), as single point screening in agonist mode at 100 µM (modulator library) and as allosteric modulators at 100 and 10 µM with increasing dose of TAK-875 and AM-5262, respectively. Following 90 minutes incubation at 37°C with ligand, cells were lysed with 40 µl 10 mM formic acid and subsequent incubation on ice for 30-60 minutes. 35 μL extract were transferred to a white 96-well plate and 60 μL of 1:8 diluted YSi poly-d-lysine coated beads (Perkin Elmer) were added. After vigorous shaking, the plate was centrifuged for 5 minutes at 1500 rpm, and β-radiation was counted on a Packard Top Count NXT counter after 8h delay. Determinations were made in duplicates.
Competition binding assay The day following seeding, the cells were washed with HEPES wash buffer (50 mM HEPES, 5 mM MgCl2, 1 mM CaCl2 (pH=7.2) + 0.1 % free fatty acid free BSA). Afterwards, 50 µl cold binding buffer was added (HEPES wash buffer + 100 µg/ml bacitracin) and incubated at 4°C in 15 min. Increasing doses of TAK-875 and comp. 1 were added to the binding buffer and immediately after, 50 µl tracer solution containing 3 H-TAK-875 (5,000 cpm/well) was added. Plates were incubated for 3 h. After the incubation, cells were washed twice with 200 µl in HEPES wash buffer and 50 µl/well Microscint20 was added. Plates were covered with TopSeal (PerkinElmer) and γ-radiation was counted on a Packard Top Count NXT counter.
Enzyme inhibition assay
AmpC β-lactamase inhibition was measured in 50 mM potassium phosphate, pH 7.0, at room temperature. The known aggregator 3′,3′′,5′,5′′-tetraiodophenolphthalein (TIPT, AH Diagnostics, Denmark), TAK-875 and comp. 1 (31.6 μM, final concentration) were diluted from a 10 mM stock in 100% DMSO with final concentrations of DMSO of 1 % (v/v). E.coli AmpC β-Lactamase (4.66 µg/ml, final concentration, ProspecBio, Israel) was added to the samples and the compounds (TIPT, TAK-875, comp. 1) were added subsequently. The mixture was incubated for 5 min with and without 0.01% (v/v) Triton X-100; the reaction was initiated by adding 3 μL CENTA substrate (266 mM final concentration, Merck, USA). Change in absorbance was monitored at 405 nm for 5 min using an HP 8453 UV-vis spectrophotometer (Clariostar, BMG Labtech GmbH, Germany). The assay was performed in duplicates in 96-well plates. Enzyme inhibition was defined as:
where vi and vc are the inhibited and uninhibited rates of reaction, respectively.
Compound synthesis
All reagents, materials and solvents used in the disclosed synthetic method are commercially available. 7-((4-amino-6-(o-tolylamino)-1,3,5-triazin-2-yl)methoxy)-4-methyl-2H-chromen-2-one (compound 1)
A solution of 7-hydroxy-4-methyl-2H-chromen-2-on (0.407 g, 2.31 mmol) in tetrahydrofuran (20 mL) was treated with 6-(chloromethyl)-2-N-(2-methylphenyl)-1,3,5-triazine-2,4-diamine (0.577 g, 2.31 mmol) and potassium carbonate (0.958 g, 6.93 mmol). The resulting mixture was stirred at reflux under argon for 16 h. Upon completion of the reaction the mixture was filtered through a pad of celite and the filtrate was evaporated. The residue after evaporation was subjected to a column chromatography on silica gel eluting with a dichloromethane -ethyl acetate mixture (gradient 20:1-1:1) to afford the title compound Table S1 . Mutational mapping of the three binding sites of FFAR1 for TAK-875, AM-5262 and compound 1. Pharmacological activity of different FFAR1 mutants located in the three binding sites upon stimulation by TAK-875, AM-5262 and compound 1, as determined by IP accumulation. The constructs were expressed in transiently transfected COS7 cells. Potency foldchanges are indicated as EC50 fold-changes compared to wildtype (WT) FFAR1. Potency changes of more than 10-fold are highlighted in bold. N.D.: non-determinable.
Smiles
Z224403310 Table S2 . Smiles and vendor IDs of the 99 compounds (library #1) that were selected in a structure-based screening and tested experimentally. Table S3 . Smiles and vendor IDs of the 96 commercially available analogues of comp. 1 (library #2) that were tested experimentally.
